Clinical Trials: Clinical Trials in India

CDSCO’s Role in Fast-Tracking Critical Trials in India

Posted on digi By digi

India’s CDSCO has shown commendable adaptability in enabling accelerated access to critical therapies, especially during emergencies like COVID-19. Through a blend of NDCTR provisions, ad hoc guidances, and reliance on foreign approvals, the regulatory system supports both innovation and patient safety. However, fast-tracking is not a shortcut—it requires rigorous data, strategic planning, and robust post-approval controls. Sponsors who prepare proactively and align with CDSCO expectations stand to benefit from faster timelines without regulatory compromise.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Phase 4 Studies in India: Post-Approval Commitments Explained

Posted on digi By digi

Phase IV clinical trials represent a critical link in India’s drug safety framework, helping to monitor drug behavior in real-world settings and diverse populations. CDSCO’s structured post-approval commitments, especially under NDCTR 2019, reflect the country’s evolving maturity in pharmacovigilance and regulatory science. Sponsors must treat these studies with the same rigor as pre-approval trials and leverage them not just for compliance, but for long-term therapeutic success and market trust.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Indian Regulatory Support for Orphan Drugs: CDSCO and NDCTR Framework

Posted on digi By digi

India has made commendable strides in supporting orphan drug development through its regulatory apparatus. With clearly defined provisions in NDCTR 2019, clinical trial waivers, fast-track reviews, and policy-level interventions under NPRD 2021, the country is better positioned to address the therapeutic gap in rare disease care. For sponsors and stakeholders, early engagement with regulators and ethical diligence remain the key to leveraging India’s supportive ecosystem for orphan drugs.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Medical Device Clinical Trials in India: Regulatory Framework and CDSCO Pathways

Posted on digi By digi

India’s medical device regulatory landscape is maturing, with defined provisions for clinical trials, ethics oversight, and post-market vigilance. Sponsors must navigate a separate pathway under the MDR 2017, distinct from drug trials governed by NDCTR. With increasing demand for device innovation and localization, India offers opportunities for early-phase device research backed by regulatory clarity, structured processes, and global harmonization. Proactive engagement with CDSCO and adherence to ISO 14155 can ensure compliance and trial success.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Adaptive Trial Designs in Indian Clinical Programs: Regulatory Perspectives and Emerging Practices

Posted on digi By digi

Adaptive trial designs offer Indian sponsors and global collaborators a powerful tool for efficient, ethical, and informative clinical research. While CDSCO does not yet offer formal guidance, there is growing recognition of adaptive methods, particularly in complex and urgent therapeutic areas. Early engagement with regulators, rigorous design planning, and transparent communication with stakeholders are essential to successfully implementing adaptive designs in the Indian clinical trial landscape.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Role of NABH Accreditation in Clinical Trial Site Selection in India

Posted on digi By digi

Incorporating NABH accreditation as a clinical trial site selection criterion in India provides measurable benefits in quality, compliance, and operational excellence. While not a regulatory requirement, NABH-accredited institutions align with global GCP standards, enhance audit readiness, and contribute to reliable trial conduct. As India’s clinical trial landscape expands, leveraging NABH as a quality marker will support more consistent and inspection-resilient trial execution.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

How CTRI Enhances Transparency in Indian Clinical Trials

Posted on digi By digi

CTRI is more than a registration portal—it is a transparency enabler and ethical safeguard for clinical research in India. By mandating public disclosure of trial parameters, CTRI strengthens trust among participants, regulators, and sponsors. Proper use of CTRI not only ensures regulatory compliance but also enhances scientific credibility and international alignment. As India advances as a global trial hub, the role of CTRI will only become more pivotal in upholding research integrity.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Phase 3 Vaccine Trials Conducted in India: Regulatory Insights and Case Studies

Posted on digi By digi

Phase 3 vaccine trials are a cornerstone of public health preparedness and scientific credibility. India’s robust execution of multiple COVID-19 vaccine trials demonstrated operational excellence, regulatory responsiveness, and scientific integrity. With its well-established infrastructure and evolving policies, India is poised to remain a key hub for global vaccine research and development, far beyond the COVID-19 era.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Emerging Role of Decentralized Trials in India: Regulatory Landscape and Implementation Insights

Posted on digi By digi

Decentralized clinical trials offer immense potential for transforming India’s clinical research ecosystem by improving accessibility, patient-centricity, and trial efficiency. While the regulatory framework continues to evolve, proactive engagement with Ethics Committees, adherence to GCP standards, and strategic investment in digital tools can ensure successful implementation of DCTs in India. Sponsors who embrace this shift today will be better positioned for the future of global clinical research.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Clinical Data Protection Under Indian IT Act and DPDP Act: What Sponsors and Investigators Must Know

Posted on digi By digi

India’s data protection landscape is evolving rapidly, and clinical trial stakeholders must align their operations with both regulatory and ethical expectations. By harmonizing Good Clinical Practice (GCP) with the provisions of the IT Act and the DPDP Act, sponsors and CROs can safeguard patient confidentiality, ensure trial compliance, and avoid significant legal and reputational risks. Proactive planning, staff training, and robust documentation are essential to stay ahead of India’s maturing data protection enforcement regime.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials